⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
IDYA News
IDEAYA Biosciences, Inc. Common Stock
IDEAYA Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides a Business Update
prnewswire.com
IDYA
IDEAYA Biosciences to Participate in Upcoming February 2026 Investor Relations Events
prnewswire.com
IDYA
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
prnewswire.com
IDYA
Servier delivers solid performance in 2024/25 and confirms its forecasts for 2030 USA - English USA - English USA - Français
prnewswire.com
IDYA
Servier affiche une performance solide en 2024/25 et confirme ses projections pour 2030 USA - Français USA - English USA - English
prnewswire.com
IDYA
IDEAYA Biosciences Provides a Business Update and Outlines 2026 Corporate Objectives at the 44th Annual J.P. Morgan Healthcare Conference
prnewswire.com
IDYA
IDEAYA Biosciences Announces Participation at the 44th Annual J.P. Morgan Healthcare Conference
prnewswire.com
IDYA
IDEAYA Biosciences Completes Targeted Full Enrollment in Randomized Pivotal Phase 2/3 Trial (OptimUM-02) of Darovasertib in Combination with Crizotinib in First-line HLA*A2-Negative Metastatic Uveal Melanoma
prnewswire.com
IDYA
IDEAYA Biosciences Announces IND Submission for IDE574, a Potential First-In-Class KAT6/7 Dual Inhibitor for Breast and Lung Cancers
prnewswire.com
IDYA
バイオサイトジェンがIDEAYAにライセンスした二重特異性ADC「IDE034」、FDAからIND承認を取得
businesswire.com
IDYA